EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer
Osimertinib is the latest generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor used for patients with EGFR-mutated non-small cell lung cancer (NSCLC). We aimed to explore the novel mechanisms of osimertinib by particularly focusing on EGFR-independent effects, which have not...
Main Authors: | Ren Nanamiya, Ryoko Saito-Koyama, Yasuhiro Miki, Chihiro Inoue, Teeranut Asavasupreechar, Jiro Abe, Ikuro Sato, Hironobu Sasano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/16/8522 |
Similar Items
-
Biochemical and biophysical characterization of four EphB kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles
by: Ross C. Overman, et al.
Published: (2013-06-01) -
A Chemical-Genetic Study of EphB Receptor Tyrosine Kinase Signaling in the Developing Nervous System
by: Soskis, Michael
Published: (2012) -
Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma
by: Shilpa Bhatia, et al.
Published: (2017-03-01) -
Optogenetic activation of EphB2 receptor in dendrites induced actin polymerization by activating Arg kinase
by: Clifford Locke, et al.
Published: (2017-12-01) -
EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model
by: Xiaokun Yang, et al.
Published: (2015-09-01)